Long-Read Sequencing Resolves Atypical Facioscapulohumeral Dystrophy Loci

Closing the Diagnostic Gap in Facioscapulohumeral Dystrophy

Facioscapulohumeral dystrophy remains one of the most prevalent autosomal dominant muscle disorders, yet its complex genetic architecture continues to challenge routine clinical diagnostics [1, 2]. While the majority of cases stem from a contraction of the D4Z4 macrosatellite array (a large, repeating DNA segment) on chromosome 4q35, the highly repetitive nature of these regions makes them difficult to sequence and assemble accurately [3, 4]. Current gold-standard assays often struggle to capture the full spectrum of pathogenic variations, particularly when epigenetic deregulation (chemical modifications that alter gene expression without changing the underlying DNA sequence) occurs in the absence of classic deletions [5, 6]. Researchers using the Telomere-to-Telomere human genome assembly have identified that D4Z4-like repeats are actually distributed across at least ten additional chromosomes, which can lead to off-target amplification and diagnostic errors when using standard primer sets [3]. As the field moves toward targeted therapies, precise molecular characterization has become a prerequisite for trial readiness and effective patient management [7, 8, 9]. To address this, a recent study investigates how long-read sequencing (a technique that analyzes extended, continuous DNA fragments to span complex genomic regions) can resolve the most elusive structural variants and methylation patterns at these critical loci [4, 10].

The Genetic Landscape of FSHD1 and FSHD2

Facioscapulohumeral dystrophy (FSHD) is primarily associated with the contraction of the D4Z4 macrosatellite array, a large, repeating DNA segment located at the 4q35 locus on chromosome 4. In the general population, unaffected individuals typically carry between 11 and 150 D4Z4 repeats. However, approximately 95% of patients diagnosed with FSHD, classified as FSHD1, exhibit a contraction to only 1 to 10 D4Z4 units. This structural contraction is fundamentally linked to reduced DNA methylation at the 4q35 locus, a chemical modification that normally keeps the region transcriptionally silent. When these repeats are lost and methylation is reduced, the DUX4 gene is inappropriately expressed, leading to the progressive muscle wasting characteristic of the disorder.

Beyond the common FSHD1 subtype, approximately 3% of patients present with FSHD2, which arises from a digenic mechanism (a disease state caused by the interaction of two different genetic factors). These individuals do not necessarily have the D4Z4 contraction seen in FSHD1 but instead carry a pathogenic variant in the SMCHD1 gene (Structural Maintenance of Chromosomes flexible Hinge Domain containing 1). This mutation leads to the epigenetic deregulation of the 4q35 locus, effectively mimicking the loss of gene silencing observed in contraction-based cases. Despite these established pathways, a diagnostic gap persists. Between 1% and 2% of clinically diagnosed FSHD patients lack a defined genetic cause after standard testing. These individuals exhibit the classic muscle weakness patterns of the disease but do not harbor the typical D4Z4 contractions or SMCHD1 mutations, leaving their molecular drivers unidentified and complicating clinical management.

Resolving Complex Variants at the Nucleotide Level

To address the diagnostic gap in patients who present with classic symptoms but lack standard genetic markers, researchers identified a cohort of more than 70 patients clinically diagnosed with FSHD who carry a complex structural variant of the 4q35 or 10q26 loci. These regions are notoriously difficult to map using short-read sequencing due to their repetitive nature and high homology (similarity in sequence) between chromosomes 4 and 10. To resolve these complexities, the study performed detailed structural analyses on seven representative cases selected for their unique structural variants at these loci. By employing high-resolution long-read sequencing technologies, specifically Oxford Nanopore and PacBio, the team was able to span large, repetitive DNA segments that traditional methods often fail to capture accurately.

The use of these advanced sequencing platforms allowed the researchers to resolve the architecture and methylation patterns across the 4q35 and 10q26 loci at the nucleotide level, providing a granular view of the genetic rearrangements. The analysis revealed that the duplicated alleles in these atypical cases do not occur randomly. Instead, they arise from intrachromosomal recombination (a reshuffling of genetic material within the same chromosome) between LSau elements (specific repetitive DNA sequences) contained within the D4Z4 array and distal subtelomeric beta-satellite elements (structural DNA near the ends of chromosomes). This specific recombination event is clinically significant because it produces variable deletions within the proximal D4Z4 region, effectively altering the local genomic environment in a way that may facilitate the pathogenic expression of DUX4.

A critical finding for clinical geneticists is that the breakpoints for these deletions differ among individual patients, suggesting that while the mechanism of recombination is shared, the resulting genetic signature is highly personalized. Because these complex structural variants involve large-scale rearrangements and duplications that maintain a high degree of sequence identity, they are often invisible to standard diagnostic tools. The researchers noted that these variants are not detectable using standard technologies, such as Bionano Optical Genome Mapping (a technique that creates physical maps of whole genomes to detect large structural variations), and currently require manual curation for identification during routine molecular diagnosis procedures. This level of resolution confirms that structural variants may be considered likely pathogenic even in the absence of an SMCHD1 variant, provided the structural and epigenetic features align with the FSHD phenotype.

Clinical Implications for Atypical Presentations

For clinicians managing patients with suspected facioscapulohumeral dystrophy who present with classic symptoms but negative results on standard tests, the limitations of current diagnostic platforms represent a significant hurdle. The study demonstrates that these complex structural variants are not detectable using standard technologies such as Bionano Optical Genome Mapping, a tool often relied upon for identifying large-scale genomic rearrangements. Because these variants involve intricate duplications and deletions at the 4q35 and 10q26 loci that maintain high sequence identity, their identification requires manual curation during routine molecular diagnosis procedures rather than relying solely on automated bioinformatics pipelines. This manual oversight ensures that subtle rearrangements, which might otherwise be dismissed as technical artifacts, are correctly identified in the 1% to 2% of patients with atypical molecular profiles.

Beyond mere identification, the clinical challenge lies in interpreting the functional impact of these rearrangements. The researchers emphasize that determining the pathogenic relevance of these rearrangements requires the integration of structural and epigenetic features, such as DNA methylation patterns (chemical modifications to DNA that regulate gene expression) at the 4q35 locus. Traditionally, clinicians look for variants in the SMCHD1 gene to explain the epigenetic deregulation seen in FSHD2. However, this study clarifies that structural variants may be considered likely pathogenic even in the absence of an SMCHD1 variant. By combining high-resolution long-read sequencing with epigenetic analysis, clinicians can confirm whether a specific structural rearrangement leads to the chromatin relaxation (the unspooling of tightly packed DNA that allows genes to be turned on) and DUX4 expression characteristic of the disease.

These findings have immediate utility for the management of patients who have previously been labeled as genetically unsolved. A comprehensive analysis of 4q35 structural variants is necessary to refine diagnosis, guide genetic counseling, and improve clinical care for individuals who do not fit the standard FSHD1 or FSHD2 categories. For the practicing physician, this means that a negative result from conventional testing or optical mapping does not rule out a genetic basis for the patient's muscular dystrophy. Accurate molecular characterization allows for more precise prognostic discussions and ensures that patients and their families receive appropriate counseling regarding inheritance risks and potential future therapeutic interventions.

References

1. Schätzl T, Todorow V, Kaiser L, et al. Meta-analysis towards FSHD reveals misregulation of neuromuscular junction, nuclear envelope, and spliceosome. Communications Biology. 2024. doi:10.1038/s42003-024-06325-z

2. Giardina E, Camaño P, Burton‐Jones S, et al. Best practice guidelines on genetic diagnostics of facioscapulohumeral muscular dystrophy: Update of the 2012 guidelines. Clinical Genetics. 2024. doi:10.1111/cge.14533

3. Salsi V, Losi F, Pini S, Chiara M, Tupler R. Rethinking genomics of facioscapulohumeral muscular dystrophy in the telomere-to-telomere era: pitfalls in the hidden landscape of D4Z4 repeats.. European journal of human genetics : EJHG. 2026. doi:10.1038/s41431-025-02000-x

4. Xiao L, Semwal A, John BS, et al. Complete genetic and epigenetic architecture of D4Z4 macrosatellites in FSHD, BAMS, and reference cohorts with D4Z4End2End. Genome Research. 2026. doi:10.1101/gr.280907.125

5. Hiramuki Y, Kure Y, Saito Y, et al. Simultaneous measurement of the size and methylation of chromosome 4qA-D4Z4 repeats in facioscapulohumeral muscular dystrophy by long-read sequencing. Journal of Translational Medicine. 2022. doi:10.1186/s12967-022-03743-7

6. Belayew A, Rosa AL, Zammit PS. DUX4 at 25: how it emerged from “junk DNA” to become the cause of facioscapulohumeral muscular dystrophy. Skeletal Muscle. 2025. doi:10.1186/s13395-025-00388-0

7. Ghasemi M, Emerson CP, Hayward LJ. Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials. Cells. 2022. doi:10.3390/cells11040687

8. Yeow D, Rudaks LI, Davis RL, et al. Long-read sequencing for diagnosis of genetic myopathies. BMJ Neurology Open. 2025. doi:10.1136/bmjno-2024-000990

9. Owusu R, Savarese M. Long-read sequencing improves diagnostic rate in neuromuscular disorders.. Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology. 2023. doi:10.36185/2532-1900-394

10. Huang M, Zhang Q, Wu S, et al. Accurate detection of D4Z4 repeats, methylation and allele haplotype in facioscapulohumeral muscular dystrophy 1 using nanopore long-read adaptive sampling sequencing: a pilot study.. Journal of medical genetics. 2025. doi:10.1136/jmg-2025-110827